IBD Patients to Benefit From SonarMD Partnership With Digestive Healthcare Center

IBD Patients to Benefit From SonarMD Partnership With Digestive Healthcare Center
0
(0)

Illinois-based SonarMD recently announced a collaboration with New Jersey’s Digestive Healthcare Center to improve care for patients with inflammatory bowel disease (IBD), including Crohn’s disease.

Under the terms of the collaboration, the Digestive Healthcare Center will be the first clinic of gastroenterology not only in New Jersey, but also in the Northeast to have complete access to the SonarMD platform, a revolutionary, web-based application that enables doctors to monitor the health status of their patients between appointments through electronic health evaluation surveys.

Using evidence-based nationwide guidelines, the SonarMD technology operates a Patient Reported Outcomes score to every survey submission, notifying the clinician to probable down-trends in the health status of patients. If clinicians intervene early, those health trends can be reversed, leading to fewer hospitalizations and better care outcomes.

The SonarMD platform delivers care algorithms to help providers and patients dramatically improve the management of chronic diseases in the new era of value-based care.

The first release of the SonarMD platform has been deployed for patients with Crohn’s disease at the Illinois Gastroenterology Group (IGG). As managing associate of the IGG, Kosinski has been an innovator in health management solutions.

In collaboration with the Blue Cross/Blue Shield of Illinois, Kosinski spearheaded the development of the first Intensive Medical Home for Crohn’s disease management, making a triad of payer, patient, and healthcare provider. All three benefit from the success of the program in lowering healthcare costs while offering better care delivery.

Digestive Healthcare Center is part of a national SonarMD technology roll-out, incorporating some of the country’s best practices for IBD.

“For the first time, practices from across the country dealing with the complexities of Crohn’s care have access to a common analytical data source which grows more relevant with each new group of participants,” Kosinski in a press release. “This data not only helps practitioners establish a shared set of best practices for their high-risk patients but, in the process, also provides substantial benefits to patient insurance providers through reduced medical costs.”

Tracey Powell, SonarMD CEO, said, “As we continue to see and document the significant, positive effects that use of the SonarMD platform is having on patient healthcare outcomes, we are creating a road map for other organizations struggling with the transition from fee-for-service to the value-based care model. It is an exciting time for us, practitioners, and the patients they serve.”

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • BBT-401 trial data
  • fCAL Elisa protein test
  • Infliximab
  • antibodies, ulcerative colitis

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?